Adults with type 2 diabetes in the UK now have a licensed basal insulin that is injected once a week rather than once a day. The Medicines and Healthcare products Regulatory Agency (MHRA) authorised insulin efsitora alfa, sold as Onswik, on 13 October. The change could cut scheduled basal-insulin injections from as many as 365 a year to 52, but it does not make the medicine suitable for everyone.
What the authorisation covers
The marketing authorisation granted to Eli Lilly Nederland B.V. is for treating type 2 diabetes mellitus in adults. Efsitora alfa is a long-acting basal insulin, a background treatment intended to help control glucose between meals and overnight. Insulin lowers blood glucose by helping muscle and fat cells take up glucose and by reducing glucose production by the liver. The detailed dosing instructions belong in its product information and a clinician’s treatment plan.
The MHRA says clinical trial data showed glycaemic control comparable with once-daily basal insulin treatments in adults with type 2 diabetes. The European Medicines Agency’s earlier review describes four phase 3 randomised, active-controlled QWINT trials. Across those studies, reductions in glycated haemoglobin (HbA1c), a measure of average blood glucose over time, were comparable with daily basal insulin. The observed HbA1c differences against comparators ranged from minus 0.01 to minus 0.09 percentage points in insulin-naïve and insulin-experienced groups. These findings support similar glucose-lowering performance in the studied populations; they do not show that a weekly schedule improves control for every person or that it prevents complications better.
Fewer injections, but not a universal switch
A weekly schedule may be practically important for people who find daily injections difficult, or who need help to take insulin. NICE’s final draft appraisal guidance identifies possible advantages for some people who are frail, have a learning disability, have limited manual dexterity or visual, cognitive or sensory impairment, or have difficulty fitting daily insulin into working life. These are potential groups for whom the regimen may be useful, not a rule that every person with one of these circumstances should receive it.
Basal insulin is generally considered within an individualised plan when other treatment has not achieved the required glucose control. NICE’s appraisal describes efsitora as an option for the same population considered for basal insulin taken once or twice a day, with treatment choice discussed between the person and healthcare professional. The appraisal says the least expensive suitable option should be used after considering advantages and disadvantages, dose, administration costs and commercial arrangements. A convenient schedule is therefore one factor in a decision that also depends on clinical needs, other health conditions and the person’s preferences.
The appraisal’s evidence has limits. NICE noted that people who might benefit most from a weekly injection were underrepresented in trials, adding uncertainty about the treatment effect in those groups. It also said the scale of any saving from less support with injections varies between settings. Comparisons of overall costs assume similar health benefits to other basal insulins and that some patients need help to inject. The committee’s conclusion was that the medicine could be an option, not that all patients would save money or require less support.
Safety and access
Hypoglycaemia, or low blood sugar, was the most common adverse reaction reported with efsitora alfa. This is a recognised risk that matters with insulin treatment and requires patients and clinicians to consider individual monitoring and management. The MHRA says it will continue safety surveillance. Patients should not change or stop prescribed insulin without discussing it with their diabetes team.
The regulatory decision and NHS access are related but distinct. NICE’s final draft guidance had been conditional on MHRA licensing, which has now been granted. The appraisal document states that final guidance will be published after licensing and that, once final recommendations are published, NHS funding arrangements apply to the population and conditions specified in the guidance. Its stated implementation period is 90 days in England and usually 60 days in Wales. The authorisation alone does not establish immediate availability in every clinic or eligibility for every patient; the final NICE wording, local implementation and individual clinical judgement remain relevant.
For now, the practical significance is a newly licensed weekly alternative within adult type 2 diabetes care. The reduction in injection frequency is clear; the best choice of insulin remains specific to the person, the evidence base and the service in which care is delivered.
